Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma by Powles, T et al.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Author afﬁliations appear at the end of this
article.
Published online ahead of print at
www.jco.org on March 7, 2016.
Supported by Genentech, South San
Francisco, CA.
Presented in part at the 50th Annual
Meeting of the American Society of
Clinical Oncology, Chicago, IL, May 30-
June 3, 2014, and at the American
Association for Cancer Research Special
Conference: Targeting the PI3K-mTOR
Network in Cancer, Philadelphia, PA,
September 14-17, 2014.
Authors’ disclosures of potential conﬂicts
of interest are found in the article online at
www.jco.org. Author contributions are
found at the end of this article.
Clinical trial information: NCT01442090.
Corresponding author: Thomas Powles,
MD, Barts Experimental Cancer Medicine
Centre, Barts Cancer Institute, Queen
Mary University of London, London EC1A
7BE, United Kingdom; e-mail: thomas.
powles@bartsandthelondon.nhs.uk.
© 2016 by American Society of Clinical
Oncology
0732-183X/16/3414w-1660w/$20.00
DOI: 10.1200/JCO.2015.64.8808
Randomized Open-Label Phase II Trial of Apitolisib
(GDC-0980), a Novel Inhibitor of the PI3K/Mammalian
Target of Rapamycin Pathway, Versus Everolimus in Patients
With Metastatic Renal Cell Carcinoma
Thomas Powles, Mark R. Lackner, Ste´phane Oudard, Bernard Escudier, Christy Ralph, Janet E. Brown,
Robert E. Hawkins, Daniel Castellano, Brian I. Rini, Michael D. Staehler, Alain Ravaud, Wei Lin, Bridget O’Keeffe,
Yulei Wang, Shan Lu, Jill M. Spoerke, Ling-Yuh Huw, Michelle Byrtek, Rui Zhu, Joseph A. Ware, and
Robert J. Motzer
A B S T R A C T
Purpose
To the best of our knowledge, this study is the ﬁrst to compare dual inhibition of PI3K/mammalian target
of rapamycin (mTOR) by apitolisib (GDC-0980) against single inhibition of mTORC1 by everolimus in
metastatic renal cell carcinoma (mRCC).
Patients and Methods
Patients with clear-cell mRCC who progressed on or after vascular endothelial growth factor–
targeted therapy were randomly assigned to apitolisib 40 mg once per day or to everolimus 10 mg
once per day. End points included progression-free survival, safety, overall survival, and objective
response rate. Biomarker assessments were conducted.
Results
Eighty-ﬁve patients were randomly assigned. After 67 events, stratiﬁed analysis revealed that
median progression-free survival was signiﬁcantly shorter for apitolisib than for everolimus (3.7 v
6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P , .01]); apitolisib was not favored in any
stratiﬁcation subgroup. Median overall survival was not signiﬁcantly different but trended in favor of
everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]). The objective
response rate was 7.1% for apitolisib and 11.6% for everolimus. Patients administered apitolisib
with a greater incidence of grade 3 to 4 adverse events were more likely to discontinue treatment
(31% v 12% for everolimus). No drug-related deaths were observed. Apitolisib in comparison with
everolimus was associated with substantially more high-grade hyperglycemia (40% v 9%) and rash
(24% v 2%). Apitolisib pharmacokinetics suggested a relationship between exposure, and rash and
hyperglycemia. Retrospective biomarker analyses revealed a relationship between VHL mutation
status and outcome with everolimus but not with apitolisib. High hypoxia-inducible factor 1a protein
expression was associated with better outcome in both arms.
Conclusion
This study demonstrated that dual PI3K/mTOR inhibition by apitolisib was less effective than was
everolimus in mRCC, likely because full blockade of PI3K/mTOR signaling resulted in multiple on-
target adverse events. VHLmutation and hypoxia-inducible factor 1a expression may be predictive
of an mTOR inhibitor beneﬁt, although prospective validation is required.
J Clin Oncol 34:1660-1668. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Targeted therapies directed towards key signaling
pathway components, including vascular endo-
thelial growth factor (VEGF) and mammalian
target of rapamycin (mTOR), are currently the
standard of care for metastatic clear-cell renal cell
carcinoma (RCC), although their absolute clinical
beneﬁt remains limited.1,2 Up to 70% of RCC cases
are of the clear cell type, and approximately 90% of
patients with clear-cell RCC exhibit somatic loss of
VHL gene expression through genetic/epigenetic
mechanisms.3,4 This results in dysregulation of
hypoxia-inducible factor (HIF) 1a protein ubiq-
uitination, elevated HIF1a and HIF2a levels, and
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up-regulation of VEGF expression and signaling,5 indicating angio-
genesis seems to play a central role in clear-cell RCC.2 The activity of
mTORC1 also contributes to angiogenesis through regulation ofHIF1a
transcription and its cap-dependent translation.6,7 Thus, loss of VHL
expression and activation of mTORC1 signaling converge on enhanced
HIF expression, thereby fueling angiogenic signaling in clear-cell RCC.
The rapalogs everolimus and temsirolimus have proven clinical
efﬁcacy in advanced and metastatic RCC (mRCC).8,9 They were
designed to inhibit two structurally and functionally distinct
complexes, mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2), both of which stabilize the expression of HIF1a;
mTORC2 also stabilizes HIF2a.10 A limitation is that although
mTORC1 is sensitive to rapalogs, mTORC2 generally is not.11
Furthermore, inhibition of mTORC1 alone results in the loss of
negative feedback inhibition of mTORC2 by mTORC1.12 The
subsequent increased activation of mTORC2 not only stabilizes
HIF2a but also enhances PI3K/AKT-mediated proliferation and
cell survival.13,14 Preclinical studies including in vitro and in vivo
experiments on RCC cell lines suggest that dual inhibition of PI3K/
mTOR induces growth arrest and antitumor activity more effectively
than does inhibition of mTORC1 alone.15 Together, these obser-
vations support an approach to concurrently target mTORC1,
mTORC2, and PI3K in mRCC to improve the efﬁcacy of rapalogs.
Apitolisib is a smallmolecule pan-PI3K andmTOR (mTORC1/2)
inhibitor that potently blocks PI3K/mTOR pathway signaling in
cancer cell lines and has demonstrated signiﬁcant antitumor activity
in tumor xenografts.16 A phase I study of apitolisib demonstrated
encouraging preliminary clinical activity at the recommended phase
II dose of 40 mg.17 Here, we present the results of what we believe is
the ﬁrst randomized trial of a dual PI3K/mTOR inhibitor against
an approved mTORC1 inhibitor, everolimus, in clear-cell mRCC.
Comprehensive exploratory biomarker analysis of the PI3K/mTOR
pathway and key angiogenesis regulators was also undertaken.
PATIENTS AND METHODS
Study Design and Participants
Study PIM4973 (ROVER) was conducted in accordance with Good
Clinical Practice guidelines and the Declaration of Helsinki. Written informed
consent was obtained from all patients before enrollment in agreement with
approved protocols from the ethics committees at each study site.
This phase II, multicenter, international, open-label, randomized (1:1)
trial was designed to evaluate apitolisib versus everolimus in patients with
VEGF-refractory mRCC. Eligible patients included those 18 years of age
or older, with metastatic clear-cell RCC and progression of disease after
exposure to at least one VEGF pathway-targeted (VEGF-targeted) ther-
apy, including but not limited to, pazopanib, sunitinib, sorafenib, and
bevacizumab. Exposure to mTOR inhibitors was an exclusion criterion.
Patients were required to have measurable disease by Response Evaluation
Criteria in Solid Tumors (RECIST) v1.118 and to be randomly assignedwithin
6 months of stopping VEGF-targeted therapy. A Karnofsky performance
status of at least 70%, as well as adequate bone marrow and liver/renal
function, were required. Untreated brain metastases and unstable medical
conditions such as cardiac disease and diabetes were exclusion criteria.
Random Assignment and Masking
Random assignment of eligible patients using a dynamic hierarchical
randomization algorithm19 was performed through an interactive voice
response system. Patients were stratiﬁed according to Memorial Sloan
Kettering Cancer Center (MSKCC) prognostic score20 (favorable, inter-
mediate, or poor) and time to progression after starting their ﬁrst VEGF-
targeted therapy (progressive disease [PD] # 6 months or . 6 months).
Procedures
Each treatment cycle was 28 days. Patients received once-per-day oral
doses of apitolisib 40 mg or everolimus 10 mg. Study treatment continued
until disease progression, intolerable toxicity, elective patient withdrawal
from the study, or study completion/termination. Crossover was not per-
mitted within the study. Dose interruptions of up to 28 days and reductions
(5 mg for everolimus; 30 mg or 20 mg for apitolisib) were permitted. Clinical
safety assessments occurred every 4 weeks until 30 days after the last dose of
study treatment. Tumors were assessed every 8 weeks until progression of
disease (RECIST v1.1) or patient withdrawal from the study, and survival
status was collected until death or patient withdrawal from the study. Adverse
events (AEs) were graded according to the National Cancer Institute’s
Common Terminology Criteria for AEs, v3.0. An internal monitoring
committee convened on a regular basis to review all available safety data.
Pharmacokinetic and Biomarker Analyses
For patients receiving apitolisib, pharmacokinetic (PK) analysis was
performed on plasma samples collected at day 1 of week 1 (predose and 1,
2, 4, and 24 hours after dose), week 3 (predose and 2 hours after dose), and
week 9 (predose and 2 hours after dose). For patients receiving everolimus,
whole-blood samples were collected at day 1 (weeks 1 and 9, predose and
2 hours after dose). Biomarker analyses were conducted on archival tumor
tissue using a targeted next-generation sequencing platform, MMP-
seq, as described previously.21 The assay used a tiled polymerase chain
reaction–based enrichment strategy to amplify 963 amplicons covering 88
oncogenes and tumor suppressors, followed by sequencing on the Illumina
GAIIx platform. The assay gave complete coverage (including all exons and
intron-exon junctions) for PIK3CA, PTEN, VHL, PBRM1, and numerous
other PI3K- and mTOR-related genes relevant to this study. PTEN and
HIF1a protein levels in tumor samples were quantitated by standard
methods of immunohistochemistry, using antibody clones CST 138G6 and
BD 54, respectively. PTEN was scored using the H-Score method, in which
the percentage of tumor cells at four staining intensities results in a score
from 0 (no staining) to 300 (high staining in 100% of tumor cells). PTEN
lowwas deﬁned as H-Score# 150. HIF1awas scored qualitatively as either
low (0% to 5% of tumor cells stained) or high (. 5% of tumor cells
stained). mRNA expression analysis for a panel of 96 genes, including
PI3K/mTOR pathway, angiogenesis, and RCC-related genes (Appendix Fig
A1, online only), was performed using the Fluidigm platform. Assays were
validated for speciﬁcity and linearity as described previously.22,23
Statistical Analysis
This phase II study was designed to provide preliminary evidence of
the activity of apitolisib versus everolimus and was only able to detect a
large beneﬁt with reasonable precision. With 60 events, the 95% CI at a
target hazard ratio (HR) of 0.6 would be 0.39 to 0.92. The primary end
point was progression-free survival (PFS), deﬁned as the time from
random assignment to disease progression, as assessed by the investigator
(RECIST v1.1), or death from any cause. Secondary end points included
conﬁrmed objective response rate, which was based on investigator
assessment, and overall survival (OS), deﬁned as the time from random
assignment until death by any cause. The Kaplan-Meier method was used
to estimate median PFS and OS. A stratiﬁed log-rank test was used to test
the difference in PFS and OS between treatment arms. The stratiﬁed Cox
proportional hazard model was used to calculate HRs and 95% CIs of
treatment effects. Stratiﬁcation factors (MSKCC prognostic score and time
to progression after starting ﬁrst VEGF-targeted therapy) derived from
source-veriﬁed data were presented in the analysis and may not be identical
to the values used for random assignment because of data inconsistencies.
Descriptive statistics were used to compare groups.
www.jco.org © 2016 by American Society of Clinical Oncology 1661
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RESULTS
Patients
Between October 2011 and July 2012, 85 patients were ran-
domly assigned (apitolisib: n = 42; everolimus: n = 43) at 21 sites
across the United Kingdom, France, Spain, Germany, and the
United States (Fig 1). All patients received at least one dose of the
study drug. At the time of the ﬁnal analysis (January 2014), median
patient follow-up was 16.6 months. Patients’ baseline demo-
graphics were generally balanced between the two groups but
showed imbalances in key factors, including the median number of
prior systemic treatments, the number of prior VEGF-targeted
treatments received, and in the number of target lesions (Table 1).
Efficacy
The median PFS was signiﬁcantly shorter for the apitolisib
treatment arm compared with the everolimus treatment arm
(3.7months v 6.1 months; HR, 2.12 [95%CI, 1.23 to 3.63; P,.01];
Fig 2A). OS was also shorter for the apitolisib treatment arm,
although the results did not reach statistical signiﬁcance at the
a = 0.05 level (16.5 v 22.8 months; HR, 1.77 [95% CI, 0.97 to
3.24; P = .06]; Fig 2B). The objective response rate was not
signiﬁcantly different between the treatment arms (7.1% for
apitolisib v 11.6% for everolimus; x2 P = .48).
In exploratory analyses, the impact on PFS of demographic
and baseline characteristics, including the individual stratiﬁcation
variables (MSKCC score, time to PD after ﬁrst VEGF-targeted
therapy), sex, age, line of therapy, location and extent of baseline
disease, and biomarker status (HIF1a and PTEN expression; VHL,
PBRM1, and PIK3CA gene alterations) was examined (Fig 3). The
biomarker data were available for only a subset of patients mainly
because of tissue availability. There was no signiﬁcant difference in
the baseline characteristics or clinical outcomes for those patients
with tissue for biomarker analysis and the intention to treat pop-
ulation. The treatment effect was similar across most subgroups,
favoring the everolimus treatment arm. A trend toward a greater
beneﬁt from everolimus was seen in patients with putative inacti-
vating mutations in VHL1, as described in more detail in Fig 3B.
Disposition and Safety
At the time of analysis, 80 patients (94%) had discontinued
study treatment (apitolisib: 40 patients [95.2%]; everolimus:
40 patients [93.0%]), most commonly because of disease progression
(apitolisib: 26 patients [61.9%]; everolimus: 29 patients [67.4%]).
There was a notable difference in the rate of discontinuation
because of AEs (apitolisib: 13 patients [31%]; everolimus: ﬁve
patients [12%]).
The most common treatment-related AEs (all grades) were
rash (55% v 61%), hyperglycemia (57% v 21%), diarrhea (41% v
51%), mucosal inﬂammation (26% v 47%), nausea (45% v 28%),
and fatigue (21% v 35%) for the apitolisib and everolimus
arms, respectively (Table 2). Grade 3 or worse AEs were more
frequent in patients receiving apitolisib compared with ever-
olimus (74% v 44%), and this difference was caused primarily
by differences in the rates of rash (24% v 2%) and hyper-
glycemia (40% v 9%).
Dose reductions were common in both arms (45% for
apitolisib; 40% for everolimus), although the median time to ﬁrst
dose reduction or treatment discontinuation was double in the
everolimus arm (apitolisib: 28 days; everolimus: 56 days; Appendix
Fig A2).
Table 1. Patient Demographic and Baseline Characteristics
Characteristic
Apitolisib
(n = 42)
Everolimus
(n = 43)
Age, median (range), years 61 (46-76) 62 (39-90)
Male 33 (79) 31 (72)
Region
Europe 35 (83) 33 (77)
Unites States 7 (17) 10 (23)
KPSS, $ 80% 40 (95) 42 (98)
MSKCC prognostic score*
Favorable 12 (29) 16 (37)
Intermediate 27 (64) 20 (47)
Poor 3 (7) 7 (16)
Time to PD after ﬁrst VEGF-targeted therapy*
# 6 months 11 (26) 12 (28)
. 6 months 31 (74) 31 (72)
Prior radiotherapy 11 (26) 7 (16)
No. of prior systemic therapies $ 2 15 (36) 6 (14)
$ 2 prior VEGF-targeted therapies 11 (26) 4 (9)
Prior sunitinib 22 (52) 16 (37)
$ 3 target lesions at baseline 29 (69) 19 (44)
Lung metastases 33 (79) 28 (65)
NOTE. Data are presented as No. (%) unless indicated otherwise.
Abbreviations: KPSS, Karnofsky Performance Status Scale; MSKCC, Memorial
Sloan Kettering Cancer Center; PD, progressive disease; VEGF, vascular
endothelial growth factor.
*Protocol-deﬁned MSKCC score and time to PD after ﬁrst VEGF-targeted
therapy, as calculated by the sponsor.
Patient random assignment
and stratification 
(n = 85)
Assessed for eligibility
(N = 110)
Excluded
Not meeting inclusion
Refused to participate
Other reasons
  (n = 13)
(n = 12)
(n = 0)
(n = 0)
Arm B                    (n = 43)
Everolimus
Received drug          (n = 43)
Did not receive drug (n = 0)
Arm A                       (n = 42)
Apitolisib
Received drug          (n = 42)
Did not receive drug (n = 0)
Receiving treatment   (n = 2)
Discontinued drug   (n = 40)
Death                        (n = 0)
Adverse event         (n = 13)
Patient decision       (n = 1)
Physician decision    (n = 0)
Receiving treatment  (n = 3)
Discontinued drug   (n = 40)
Death                        (n = 1)
Adverse event          (n = 5)
Patient decision       (n = 2)
Physician decision   (n = 3)
Fig 1. CONSORT diagram.
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PK and Biomarker Analyses
Given that only sparse PK data were available for ROVER,
population PK model simulations were performed to estimate api-
tolisib exposure (patient steady-state area under the curve). Generally,
the PK simulations for apitolisib were similar to those observed in
other subjects treated with apitolisib (data not shown). Exposure-
response analyses for both safety and efﬁcacy were conducted using
this simulated exposure data. No exposure-efﬁcacy relationships were
found. Although there was a trend towards higher apitolisib exposure
(simulated steady-state area under the curve) among patients who
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Fig 2. Kaplan-Meyer estimates of progression-free survival (A) and overall survival (B) for all randomly assigned patients. Hazard ratios estimated by Cox proportional
hazards regression stratiﬁed by calculated Memorial Sloan Kettering Cancer Center risk score and time to progression on ﬁrst vascular endothelial growth factor2targeted
therapy. NE, not evaluable.
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1/8 1 8
Number of target lesions at baseline
Baseline Risk Factors
Everolimus
(n = 43)
Apitolisib
(n = 42)
n n
Total
n
Median
(months)
Median
(months)
Hazard
Ratio
95% Wald
CI
Everolimus
Better
Apitolisib
Better
Everolimus
(n = 43)
Apitolisib
(n = 42)
n n
Total
n
Median
(months)
Median
(months)
Hazard
Ratio
95% Wald
CI
Everolimus
Better
Apitolisib
Better
Description of planned arm 85 6.1 42 3.7 1.70 (1.04 to 2.78)
Sex
Female 21 6.1 9 3.7 3.14 (0.91 to 10.86)
Male 64 5.8 33 3.7 1.42 (0.82 to 2.44)
Age group  65
< 65 59 6.1 28 3.6 1.60 (0.89 to 2.87)
≥ 65 26 5.6 14 5.3 1.99 (0.76 to 5.25)
Intermediate 47 6.1 27 3.6 1.86 (0.94 to 3.68)
MSKCC prognostic score*
Favorable 28 6.3 12 7.1 1.74 (0.72 to 4.20)
Poor 10 5.6 3 3.5 3.74 (0.51 to 27.30)
PDTime on first VEGF-targeted therapy*
PD ≤ 6 mo 23 5.8 11 5.3 1.10 (0.42 to 2.86)
PD > 6 mo 62 6.3 31 3.7 2.11 (1.17 to 3.78)
Prior sunitinib
No 47 5.6 20 3.7 1.36 (0.72 to 2.58)
Yes 38 8.6 22 3.7 2.42 (1.07 to 5.45)
Site of metastatic disease, lung
No 24 7.2 9 3.2 2.21 (0.84 to 5.79)
Yes 61 6.1 33 3.7 1.47 (0.82 to 2.63)
Number of previous systemic regimens
1 64 6.3 27 3.7 1.57 (0.87 to 2.81)
≥ 2 21 5.8 15 3.7 1.80 (0.62 to 5.21)
< 3 37 8.6 13 3.3 3.59 (1.55 to 8.34)
≥ 3 48
43
12
31
31
12
20
16
7
12
31
27
16
15
28
37
6
24
19 3.4 29 3.7 0.91 (0.47 to 1.73)
1/8 1 8
Baseline Risk Factors
Description of planned arm 85 43 6.1 1.70 (1.04 to 2.78)
HIF1α IHC
Low 19 9 6.3 1.75 (0.60 to 5.12)
High 56 28 8.6 1.57 (0.84 to 2.93)
PTEN IHC
Low 40 21 6.3 1.90 (0.91 to 3.97)
High 34 17 6.1 1.61 (0.72 to 3.60)
PTEN low or PIK3CA
Not present 32 17 6.1 1.45 (0.63 to 3.34)
Present 42 21 6.3 2.04 (0.99 to 4.20)
VHL
Absence of deleterious alteration 29 16 5.5 0.93 (0.39 to 2.21)
Deleterious alteration 24 15 8.6 2.96 (1.01 to 8.67)
PBRM1
Absence of deleterious alteration 39 22 5.5 1.71 (0.81 to 3.62)
Deleterious alteration 11 6 13.8
42
10
28
19
17
15
21
13
9
17
5
3.7
3.7
5.3
3.7
3.7
5.3
3.6
3.6
3.5
3.6
3.6 1.11 (0.20 to 6.16)
A
B
Fig 3. Forest plot of progression-free survival by (A) selected clinical baseline factors and (B) selected biomarkers (B). HIF, hypoxia-inducible factor; IHC, immuno-
histochemistry; MSKCC, Memorial Sloan Kettering Cancer Center; PD, progressive disease; VEGF, vascular endothelial growth factor.
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had best responses of partial response versus PD (Fig 4A), data were
limited, and overall there was no apparent correlation between
exposure and tumor response (Fig 4B). Kaplan-Meier analysis also
showed no signiﬁcant difference in PFS between patients with
apitolisib exposures above the median versus below the median (data
not shown). However, the exposure-safety relationship showed a
trend in that patients who discontinued because of an AE were more
likely to have higher exposure to apitolisib (Fig 4C). Everolimus
whole-blood trough levels were similar to those reported previously.24
Data from comprehensive molecular proﬁling consisting of tar-
geted next-generation sequencing, mRNA expression, and immuno-
histochemistry for PTEN and HIF1a were evaluated for associations
with best tumor response and PFS. Activating mutations in PIK3CA
were rare in this patient population (9%), but inactivating mutations in
VHL and high expression of HIF1a were relatively common (45% and
75%, respectively; Fig 5A). There was no apparent biomarker rela-
tionship with best tumor response; mutations in VHL, PBRM1,
PIK3CA, and PTEN were found in similar proportions in patients who
experienced stable disease/PD as opposed to partial response/complete
response (Fig 5A). However, there was a trend toward an association
between high expression of HIF1a and PFS in both treatment arms
(everolimus HR, 0.54 [95% CI, 0.23 to 1.29]; apitolisib HR, 0.53 [95%
CI, 0.23 to 1.20]) and between deleteriousVHL gene alterations andPFS
in the everolimus arm only (HR, 0.55 [95% CI, 0.24 to 1.25]; Figs 5B
and 5C). Gene expression analyses were also performed on a panel of
selected genes related to PI3K/mTOR biology and RCC. These genes
were selected from the literature and validated in cell lines/tumor
samples (Appendix Fig A1 and data not shown). This analysis identiﬁed
three genes, including MYC, SOSTDC1, and the mTOR regulator
STK11, associatedwith signiﬁcantly better PFS for everolimus compared
with apitolisib (Appendix Fig A3). Low expression of STK11, deﬁned as
below median expression, showed a PFS HR of 3.02. In contrast, no
genes were preferentially associated with beneﬁt from apitolisib.
DISCUSSION
The ROVER study is the ﬁrst randomized phase II trial to directly
compare simultaneous targeting of multiple nodes in the PI3K/
mTOR signaling pathway with isolated mTORC1 inhibition. In
preclinical studies, PI3K/mTORdual inhibitors have shown superior
activity tomTORC1-targeting rapalogs.15 However, the results of the
ROVER study failed to provide proof-of-concept for this hypothesis,
with the PI3K/mTORC1/mTORC2 inhibitor, apitolisib, substan-
tially underperforming the mTORC1 inhibitor, everolimus.
Several alternative hypotheses may help explain the outcome of
this trial. First, mTORC1may be the central node in the PI3K/AKT/
mTOR pathway in mRCC, as demonstrated by both temsirolimus
and everolimus. Inhibition of upstream PI3K and mTORC2 sig-
naling incurs excess toxicity without adding signiﬁcant beneﬁt.
The lack of frequent alterations in PIK3CA is consistent with this
hypothesis. Second, resistance to mTORC1 inhibition emerges
through activation of parallel signaling pathways; therefore, hori-
zontal inhibition may succeed where vertical inhibition has failed.
Some preclinical data suggest that PI3K/mTOR inhibition may lead
to compensatory activation of HER family receptors and the MAP
kinase pathway.25 Combination of mTOR inhibitor with inhibitors
of VEGF, EGFR, or MEK may achieve superior clinical efﬁcacy by
overcoming this bypass mechanism, although likely with increased
toxicity as shown in two previous randomized trials.26,27
Several other factors may have contributed to the lower efﬁcacy
of apitolisib relative to everolimus. First, apitolisib, like other
PI3K/mTOR dual inhibitors in development for solid tumors,28 was
poorly tolerated. Treatment exposure in patients was compromised
substantially by high-grade rash (24%) and hyperglycemia (40%),
which occurred early in the treatment course and resulted in one half
of the patients requiring treatment modiﬁcations and nearly one
Table 2. Treated-Related Adverse Events in $ 20% of Patients
Adverse Event (CTCAE v4.0)
Apitolisib (n = 42) Everolimus (n = 43)
All Grades Grade $ 3 All Grades Grade $ 3
Any adverse event 42 (100) 31 (74) 40 (93) 19 (44)
Rash* 23 (55) 10 (24) 26 (61) 1 (2)
Hyperglycemia 24 (57) 17 (40) 9 (21) 4 (9)
Diarrhea 17 (41) 3 (7) 22 (51) 1 (2)
Mucosal inﬂammation 11 (26) 4 (9) 20 (47) 4 (9)
Nausea 19 (45) — 12 (28) 1 (2)
Fatigue 9 (21) 1 (2) 15 (35) 3 (7)
Decreased appetite 14 (33) 1 (2) 8 (19) —
Vomiting 14 (33) 2 (5) 5 (12) 1 (2)
Infection† 8 (19) 2 (5) 13 (30) —
Cough 4 (10) — 11 (26) —
Epistaxis 3 (7) — 11 (26) —
Dyspnea 2 (5) — 11 (26) —
Asthenia 10 (24) 3 (7) 9 (21) 2 (5)
Dry skin 6 (14) 2 (5) 10 (23) 1 (2)
Pruritus 9 (21) 1 (2) 7 (16) —
Constipation 6 (14) — 9 (21) —
NOTE. Data are presented as No. (%).
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.
*Includes preferred terms of rash, rash maculopapular, rash pruritic, rash erythematous, and rash papular.
†Includes preferred terms of nasopharyngitis, lung infection, gingivitis, rhinitis, urinary tract infection, abscess, bronchitis, cystitis, ear infection, eczema impetiginous,
gastroenteritis, lower respiratory tract infection, oral herpes, paronychia, penile infection, sinusitis, staphylococcal infection, tooth infection, and upper respiratory tract
infection.
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third discontinuing apitolisib permanently. Rash and hyperglycemia
are common AEs observed with many pan-PI3K and dual PI3K
mTOR inhibitors and likely represent on-target effects of pathway
inhibition in normal tissues.28 Second, this study enrolled quickly, so
there was little time to apply the experience in managing apitolisib-
speciﬁc toxicities from earlier patients to later patients, in contrast to
the everolimus experience accumulated since its approval in 2009.
In addition, the treatment arms were imbalanced in terms of the
median number of prior systemic treatments, the number of prior
VEGF-targeted treatments, and the number of target lesions. Com-
pared with the everolimus arm, more than twice as many patients in
the apitolisib arm had two or more prior systemic therapies (36% v
14%), nearly three times as many patients in the apitolisib arm had
more than one prior VEGF-targeted therapy (26% v 9%), and a
higher percentage of patients in the apitolisib arm had three or more
target lesions (69% v 44%). The greater number of prior treatments
and target lesions in the apitolisib arm suggests that these patientsmay
have had more advanced disease, which may have inﬂuenced out-
comes, as seen in previous trials.29 The multivariate analyses yielding
adjusted HRs were generally consistent with the primary stratiﬁed
Cox estimate provided in Results (adjusted HRs incorporating dif-
ferent combinations of variables ranged from 1.99 to 2.62).
To our knowledge, the ROVER study presents the most
comprehensive biomarker assessment reported in an mRCC trial,
consisting of next-generation sequencing for a panel of 88 cancer-
related genes, coupled with focused biomarker assessment of key
components of mTOR signaling and the vascular biology of RCC.
However, the strength of the conclusions is limited by the small
sample size and the retrospective nature of the analyses. Nonetheless,
the ﬁndings support a model in which mTORC1 and VHL converge
on regulation of HIF1a protein levels. Mutational inactivation of
VHL, which is predicted to result in elevated HIF1a protein levels,
was associated with longer PFS in the everolimus arm, although
validation of this observation will require further clinical testing.
Consistent with this interpretation, direct analysis of HIF1a protein
levels by immunohistochemistry also showed an association
between high levels of HIF1a and longer PFS in both arms of the
study. In addition, low expression of the tumor suppressor STK11/
LKB1, which acts upstream of mTORC1 and when lost potently
activates mTOR signaling,30 was preferentially associated with
beneﬁt to everolimus. The differences observed between everolimus
and apitolisib may be a result of insufﬁcient inhibition of mTORC1
by apitolisib. Overall, suppression of mTORC1 activity preferentially
beneﬁts patients who show aberrant activation of HIF1a resulting
from VHL or STK11 loss. These analyses were based primarily on
archival tissue, and patients had received VEGF tyrosine kinase
inhibitor therapy, which could have substantially inﬂuenced tumor
biology. Although suggestive, our ﬁndings require rigorous pro-
spective validation in randomized studies of mTOR inhibitors to
determine whether these putative biomarkers can selected for
patients who may beneﬁt from mTORC1-targeted therapy in RCC.
As the ﬁrst phase II trial to evaluate dual PI3K/mTOR inhibition
in mRCC, the ROVER study conﬁrms the signiﬁcant clinical beneﬁt
of everolimus in VEGF-refractory disease and suggests that sustained
dual inhibition of the PI3K/mTOR pathway in mRCC is severely
limited by toxicity and a narrow therapeutic index, resulting in
limited efﬁcacy in RCC. The median OS for everolimus was
22 months, which is the longest reported for this drug to date. VHL
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Fig 4. Relationships between steady-state AUC and (A) types of responders, (B)
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under the curve; NE, not evaluable; OTHER, other reasons for subject discontinuation;
PD, progressive disease; PR, partial response; SD, stable disease; SLD, sum of the
longest diameters of the target lesions; WBS, withdraw by subjects.
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mutation, HIF1a protein, and STK11mRNA expression emerged as
potential pathway-related biomarkers for everolimus that warrant
prospective validation in mRCC. Simultaneous dual inhibition of the
PI3K and both mTOR complexes does not seem to be an effective
strategy for improving on mTORC1-targeted therapy in RCC.
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PI3K/mTOR pathway RCC/Metabolism Housekeeping
AKT2 FGFR2 PIK3IP1 TSC2 AMACR FH LRRK2 STC2 PPIA
EGFR FGFR3 PRR5 AQP1 FHIT MAP2 YPEL2 RPLP0
EIF4EBP1 GSK3B PTEN CA3 GAPDH PAX2 TMEM55B
ERBB2 IRS2 STK11 CA9 HBEGF PLIN2 VPS33B
ERBB3 MET TLR2 EPPK1 KRT7 RUNX3
FBXW7 PIK3CA TSC1 FABP7 LIMK2 SDS
Angiogenesis Cell growth/Differentiation
ANGPTL4 EPHA7 PDGFB BRCA1 CDC7 EFNA1 KITLG RASSF1 TGFB1
CSF1R EPHB1 PDGFRA CAV1 CDH1 FLCN MEOX2 RET TMEFF2
CXCR4 FLT1 STAT1 CCND2 CDH2 GATA3 MYC SKP2 VAV3
EPAS1 HIF1A VCAN CCNE1 CDKN1B IGF2R PBRM1 SMAD3 VIM
EPHA3 KIT VEGFA CCNG2 DTL IGFBP2 PPAP2B SOSTDC1 WT1
EPHA4 NOS3 VHL CD9 E2F1 INHBA PROM1 TGFA
Fig A1. Composition of renal Fluidigm panel. mTOR, mammalian target of rapamycin;
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Fig A2. Swimlane plot showing duration of therapy, dose reductions, and reason for discontinuation for individual patients. Each bar represents an individual patient.
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Fig A3. Signiﬁcance of individual gene expression level (P value) is given on the y-axis, and hazard ratio is given on the x-axis. dCt, Ct value relative to control genes; PFS,
progression-free survival; RCC, renal cell carcinoma.
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